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Abstract.
Background: Familial Alzheimer’s disease (fAD) is driven by genetic predispositions affecting the expression and
metabolism of the amyloid- protein precursor. Aluminum is a non-essential yet biologically-reactive metal implicated
in the etiology of AD. Recent research has identified aluminum intricately and unequivocally associated with amyloid- in
senile plaques and, more tentatively, co-deposited with neuropil-like threads in the brains of a Colombian cohort of donors
with fAD.
Objective: Herein, we have assessed the co-localization of aluminum to immunolabelled phosphorylated tau to probe the
potential preferential binding of aluminum to senile plaques or neurofibrillary tangles in the same Colombian kindred.
Methods: Herein, we have performed phosphorylated tau-specific immunolabelling followed by aluminum-specific fluores-
cence microscopy of the identical brain tissue sections via a sequential labelling method.
Results: Aluminum was co-localized with immunoreactive phosphorylated tau in the brains of donors with fAD. While
aluminum was predominantly co-located to neurofibrillary tangles in the temporal cortex, aluminum was more frequently
co-deposited with cortical senile plaques.
Conclusion: These data suggest that the co-deposition of aluminum with amyloid- precedes that with neurofibrillary
tangles. Extracellularly deposited amyloid- may also be more immediately available to bind aluminum versus intracellular
aggregates of tau. Therapeutic approaches to reduce tau have demonstrated the amelioration of its synergistic interactions
with amyloid-, ultimately reducing tau pathology and reducing neuronal loss. These data support the intricate associations
of aluminum in the neuropathology of fAD, of which its subsequent reduction may further therapeutic benefits observed in
ongoing clinical trials in vivo.
Keywords: Aluminum in human brain tissue, amyloid-, familial Alzheimer’s disease, neurofibrillary tangles, senile plaques,
tau
INTRODUCTION
The microtubule-associated protein tau in its nor-
mal physiological form supports the intracellular
assembly of microtubules, stabilizing the neuronal
cytoskeleton [1, 2]. Human tau is a natively unfolded
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protein with little secondary structure [3]. The six
isoforms of human tau arise through alternative RNA
splicing, which is defined by either three (3R) or
four (4R) microtubule-binding domain repeats [3,
4]. Tau is predominantly found in neurons in the
brain, though it is also expressed at lower glia
levels [1, 2]. Tau binds to microtubules through
its C-terminal domain with the N-terminus binding
to cytosolic components, including the membrane-
associated protein actin, the latter defining a role
for tau in the organization of cytoskeletal networks
[2, 3].
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Post-translational modifications of tau and its
phosphorylation by protein kinases, including glyco-
gen synthase kinase 3 (GSK3), have been shown to
act as a critical mediator influencing both the func-
tion and stability of tau [1–3]. Under physiological
conditions, the phosphorylation of tau modulates its
binding to microtubules in competition with kinesin
and dynein motors, thereby regulating the antero-
grade and retrograde transport of cellular cargoes,
respectively [2, 5]. In healthy neuronal cells, tau
is typically found along a concentration gradient,
increasing toward the axonal terminals of the cells
as maintained by the tau diffusion barrier of the axon
initial segment (AIS) that acts to modulate against
the retrograde transport of tau towards neuronal den-
drites and cell soma [3, 6]. The low levels of tau found
in axons are suggested to promote long-term poten-
tiation via the strengthening of synaptic terminals
[3, 7].
The excessive or hyperphosphorylation of tau
under pathophysiological conditions have defined
the tauopathies broadly encompassing neurodegen-
erative conditions, including Alzheimer’s disease
(AD) [1]. The subsequent breakdown of the AIS
that follows allows for the redistribution of tau
from axons allowing its retrograde diffusion into the
somatodendritic compartment of neurons [3, 6]. In
combination with tau detachment from microtubules
upon hyperphosphorylation, increasing intraneuronal
concentrations of the protein propagate from the
cell soma to dendrites causing the concomitant loss
of dendritic spines and neurite outgrowth [1, 3].
The increased accumulation and hyperphosphoryla-
tion of tau lead to the formation of neurofibrillary
tangles (NFTs) of the insoluble aggregated protein
[1]. In concert with synaptic dysfunction and loss,
the depolymerization of microtubules disrupts the
cytoskeletal network, thus acting to drive the pro-
gressive and mechanistic loss of affected neurons
[1, 5].
In addition to the large scale loss of neurons in
the frontal cortex and astrogliosis, intracellular NFTs
of tau protein and extracellular senile plaques of
the amyloidogenic amyloid- (A) peptide consti-
tute the principal neuropathological hallmarks of AD
[8–10]. While sporadic forms of AD typically occur
in patients aged 65 and over, familial Alzheimer’s dis-
ease (fAD) occurs at an earlier age of onset, driven
by autosomal dominant mutations in the presenilin 1
(PSEN1) and 2 (PSEN2) proteins and the transmem-
brane amyloid- protein precursor (APP) [11–13].
A42 is the principal pathogenic peptide located in
senile plaque cores [15, 16]. Mutations in PSENs are
known to increase the production of the A42 peptide
via the enhanced and sequential proteolytic cleavage
of APP via -site APP cleaving enzyme 1 (BACE1)
and -secretases [10, 12, 13].
Insoluble and aggregated forms of A in senile
plaques and hyperphosphorylated tau in NFTs dom-
inate the pathological landscape of familial and
sporadic AD brains. However, oligomeric forms of
amyloidogenic proteins are thought to underlie neu-
rotoxicity in vivo [17]. Therefore, such has continued
to lend support to an updated and genetically driven
view of the amyloid cascade hypothesis of AD,
in which the deleterious effects observed in brain
parenchyma have been cemented in the studies of
fAD [11–13, 18]. In more recent studies, A has
been shown to modulate AIS function through its
ability to activate its tethered GSK3 protein kinase
[3, 6]. The downstream phosphorylation of non-tau
targets that follows has been implicated in increased
concentrations of endogenous and exogenous tau
in the somatodendritic compartment of neurons
due to impaired microtubule dynamics in the AIS
[6, 19].
Furthermore, the ability of A to synergistically
activate cofilin, an enzyme that acts to depolymerize
actin filaments (F-actin), results in the remodeling
of cytoskeletal networks, causing the collapse of the
AIS [6]. Such demonstrates the ability of A and tau
to synergistically drive the structural disintegration
of neurons in the AD brain [1–3, 5, 6]. Interest-
ingly, cross-seeding between A and tau promotes
aggregation of amyloidogenic -pleated sheets and
NFTs, forming mutated and stable complexes rich in
aggregation-prone hydrophobic interactions [20, 21].
Those complexes formed are suggested to be aberrant
and hence contributory to AD pathology [20].
Aluminum is non-essential yet in its free solvated
and trivalent form, Al3+(aq), is biologically reac-
tive [22]. Our previous study of the brains of fAD
donors carrying a PSEN1-E280A (Glu280Ala) muta-
tion found aluminum co-localized with fibrillar A
in senile plaques [22, 23]. Donors in this kindred are
unique in that this mutation is found in large numbers
in the Antioquia region of Colombia [24]. Individuals
with fAD carrying this mutation develop elevated cor-
tical A at an early age of onset of <50 years. The high
brain aluminum content of fAD donors versus sta-
tistically lower amounts found in non-neurologically
impaired individuals has highlighted the potential for
aluminum to act as a nidus to overcome the precipi-
tation of A [23, 25].
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In addition to a role for aluminum in senile plaque
formation in fAD, we have investigated the potential
for aluminum to bind to NFTs of hyperphospho-
rylated tau protein in the same kindred [26]. The
large number of phosphate groups available on the
surface of NFTs would be expected to bind intra-
cellular aluminum with high avidity [27]. Herein, we
have performed phosphorylated (Ser202 and Thr205)
tau-specific immunolabelling to unequivocally iden-
tify NFTs in the brain tissue of Colombian fAD
donors, carrying a PSEN1-E280A mutation [28]. The
unequivocal identification of NFTs has been followed
by aluminum-specific fluorescence microscopy to
probe the potential preferential binding of aluminum
to senile plaques or NFTs in fAD brain tissue.
MATERIALS AND METHODS
Human brain tissue
Human brain tissue consisting of formalin-fixed
paraffin-embedded (FFPE) blocks were obtained
following ethical approval from Universidad de
Antioquia, Medellin, Colombia. Donor brain tissue
was received from anonymized donors with fAD, all
carrying the PSEN1-E280A mutation and research
was performed following ethical approval obtained
from Keele University, UK (ERP 2391). FFPE brain
tissue blocks of a 45-year-old female, 57-year-old
female, and 60-year-old male, all carrying a PSEN1
E280A mutation, were selected for imaging, based
upon representative depictions of aluminum and NFT
co-localization across frontal, parietal, temporal and
occipital lobes.
Microtomy
Human brain tissue blocks were cooled on wet
ice for 10 min. Ribbons of adjacent tissue sections
were prepared at a thickness of 6 m by use
of a Leica RM2025 rotary microtome fitted
with Surgipath® DB80 LX low-profile stainless-
steel blades (Leica Microsystems, UK). Sections
were floated onto ultrapure water (conductivity
< 0.067 S cm–1) at 40◦C and transferred onto
Polysine adhesion slides (Thermo Scientific, UK).
Sections were dried overnight at ambient tempera-
ture. Excess wax was removed from tissue sections
by heating at 62◦C for 20 min. Sections were allowed
to cool fully before dewaxing and rehydration proce-
dures were performed.
Dewaxing and rehydration of human brain tissue
sections
Human brain tissue sections were dewaxed with
gentle agitation in Histo-Clear (National Diagnos-
tics, US) for 3 min. Removal of any remaining wax
was performed via a second wash in fresh Histo-
Clear for 1 min. Sections were transferred into pure
(HPLC grade) ethanol (Fisher Scientific, UK) for
2 min. Rehydration of tissue sections was achieved by
transfer through an ethanol gradient (95, 70, 50, and
30% v/v) for 1 minute in each solvent. Sections were
twice washed in ultrapure water for 30 s to remove
the remaining ethanol before staining.
Lumogallion staining
Rehydrated tissue sections were placed in Copl-
in jars and fully immersed in 1 mM lumogallion
(4-chloro-3-(2,4-dihydroxyphenylazo)-2-hydroxyb-
enzene-1-sulphonic acid, TCI Europe N.V., Bel-
gium) in 50 mM PIPES, pH 7.4. For the assessment
of autofluorescence, the adjacent serial section was
immersed in 50 mM PIPES buffer, pH 7.4 only. Sec-
tions were incubated for 6 h at ambient temperature
away from light. Sections were subsequently washed
six times in fresh PIPES buffer, rinsed for 30 s in
ultrapure water and mounted under glass coverslips
with the aqueous mounting medium, Fluoromount™
(Sigma Aldrich, UK). Lumogallion staining, ThS
counter-staining (ca 0.075% w/v ThS in 50% v/v
ethanol) [23, 26], and AT8 immunolabelling were
performed and analyzed in sequence, following
each labelling method. Every such staining method
implemented was performed on the identical tissue
section.
Immunohistochemistry
All reagents for immunohistochemistry (IHC)
were purchased from Abcam, UK, unless otherwise
stated. Following analysis of lumogallion-stained tis-
sue sections, coverslips were removed via immersion
in ultrapure water with gentle agitation overnight.
Sections were rinsed thoroughly with ultrapure
water, outlined with a hydrophobic PAP pen and
transferred into a humidity chamber for all sub-
sequent staining procedures. Thereafter, IHC was
performed according to the manufacturer’s instruc-
tions. Briefly, sections were immunolabelled with an
AT8 recombinant primary anti-tau monoclonal anti-
body (rabbit) against human tau phosphorylated on
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Ser202 and Thr205 (0.472 mg/mL: Abcam, UK:
ab210703).
Antigen retrieval was performed by adding Pro-
teinase K antigen retrieval solution to sections, foll-
owed by incubation at ambient temperature for 7 min.
Sections were rinsed in 1 X Tris-buffered saline
(TBS), followed by further rinses in TBS plus 0.025%
v/v Triton X-100. Blocking was achieved by incu-
bating sections in 10% v/v normal goat serum with
1% w/v bovine serum albumin (BSA) in TBS for
2 h at ambient temperature. Pre-optimized dilutions
(1:1,000) of the unlabeled primary AT8 antibody in
TBS, including 1% w/v BSA, were applied to sections
and incubated overnight at 4◦C to ensure complete
saturation of antibody binding.
All staining procedures were performed at ambi-
ent temperature. Following AT8 labelling, sections
were rinsed with TBS, including 0.025% v/v Triton
X-100. Endogenous tissue peroxidase activity was
blocked by incubation in 0.3% v/v H2O2 in TBS
for 15 min. Sections were subsequently stained using
a rabbit-specific horseradish peroxidase (HRP) 3,3′-
diaminobenzidine (DAB) ABC IHC staining kit. A
biotinylated goat anti-polyvalent secondary antibody
was added to sections and incubated for 10 min.
Sections were washed in TBS, and HRP-labelled
streptavidin was applied for 10 min. After washing
with TBS, DAB chromogen (30 L DAB chromogen
added to 1.5 mL DAB substrate) was applied to
sections and developed by incubation for 10 min. Sec-
tions were washed in TBS and finally mounted under
glass coverslips using the aqueous mounting medium,
Faramount™ (Agilent Dako, UK).
Microscopy
Brightfield and fluorescence micrographs were
acquired using an Olympus BX50 fluorescence mic-
roscope (mercury source) equipped with a vertical
illuminator and BX-FLA reflected light attachment.
A U-MNIB3 fluorescence filter cube (bandpassλex:
470–495 nm, dichromatic mirror: 505 nm, longp-
assλem: 510 nm) was used to acquire lumogallion
fluorescence (Olympus, UK). Images were captured
using an Olympus DP74 (CMOS processor) color
camera and the OLYMPUS cellSens (Standard 3.1)
software suite. Optimal exposure times for collect-
ing lumogallion fluorescence were set automatically
by the superfluorescence (SFL) mode of the Olym-
pus DP74 camera. The same optimized exposure
settings were then subsequently fixed for each respec-
tive and corresponding autofluorescence micrograph.
Merging of fluorescence and brightfield channels was
achieved using Photoshop (Adobe Systems Inc., US).
RESULTS
Aluminum and neurofibrillary tangles are found
co-localized in familial Alzheimer’s disease
IHC labelling using an AT8 primary antibody
demonstrated the presence of flame-like NFTs in pre-
dominantly cortical brain regions of Colombian fAD
donors. Optimization of the IHC staining method
using progressive serial dilutions of the AT8 primary
antibody improved the signal to noise ratio sequen-
tially. IHC of the parietal cortex of a 60-year-old
male Colombian fAD donor using serial dilutions of
the primary AT8 antibody of 1:40, 1:80, 1:200, and
1:1,000 identified NFTs via dark brown DAB stain-
ing at every antibody dilution tested. IHC performed
in the absence of the AT8 primary antibody produced
no detectable DAB staining (see Supplementary Fig-
ure 1).
In the temporal cortex of a 45-year-old female
Colombian fAD donor, aluminum was found in neu-
ronal cells close to extracellular deposits of aluminum
as identified by an intense orange fluorescence
emission (Fig. 1A) [26]. Punctate fluorescence was
especially noted in the cell soma of neuronal cells
and was readily differentiated from the yellow/green
fluorescence of cytosolic lipofuscin deposits in neigh-
boring cells (Fig. 1A) [26]. AT8 immunolabelling for
phosphorylated tau revealed the dense and intracel-
lular immunoprecipitation of DAB via dark brown
staining (Fig. 1B).
Merging of the fluorescence (Fig. 1A) and bright-
field (Fig. 1B) channels revealed the presence of
intraneuronal aluminum and NFTs in a single neuron
(Fig. 1C). Subsequent merging of the original ThS
fluorescence channel [26] demonstrated the presence
of a peripherally located intraneuronal green fluores-
cence emission, overlaying DAB immunostaining of
phosphorylated tau. Higher magnifications demon-
strated co-localization of intracellular particulate
aluminum deposits and AT8-reactive phosphorylated
tau (Fig. 1D). Lumogallion-reactive aluminum was
also observed in neuronal cells within pia mater
of the same donor that produced an orange flu-
orescence emission versus green autofluorescence
of the non-stained section (see Supplementary Fig-
ure 2). Similarly, the merging of fluorescence and
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Fig. 1. Neuronal cells loaded with aluminum in close proximity to extracellular aluminum in the temporal cortex of a 45-year-old female
Colombian donor with familial Alzheimer’s disease. A) Intracellular aluminum (Al) in close proximity to aluminum-rich cellular debris
(orange). B) AT8 immunoreactive phosphorylated tau (pTau) in neurons (arrows) located via DAB staining in the identical section (brown). C)
Merging of lumogallion and brightfield channels depicting aluminum and pTau in the identical neuron. D) Overlay of thioflavin S fluorescence
(green) highlighting NFTs of pTau. Asterisks denote magnified inserts. Figure adapted from [26] under CC license. Magnification: X 400,
scale bars: 50 m.
brightfield channels identified aluminum co-loca-
lized with AT8-reactive DAB staining in the same
neuron (see Supplementary Figure 2).
Co-localization of aluminum and phosphorylated
tau predominates in the temporal cortex
Lumogallion staining of the temporal cortex of a
57-year-old female Colombian fAD donor revealed
lumogallion-reactive aluminum in pyramidal neu-
rons, as highlighted via an intracellular orange
fluorescence emission (Fig. 2A). Intracellular lipo-
fuscin was frequently observed as punctate yellow
fluorescence in the cytoplasm of neuronal cells in
both lumogallion-stained and non-stained tissue sec-
tions for autofluorescence. The yellow fluorescence
emission of intracellular deposits of lipofuscin was
readily distinguished from the uniform green autoflu-
orescence of the adjacent serial section (Fig. 2C).
Subsequent AT8 immunolabelling of the identi-
cal lumogallion-stained tissue section revealed dark
brown DAB precipitation appearing as a classi-
cal flame-like NFT in a single pyramidal neuron
(Fig. 2B). Merging of lumogallion fluorescence
(Fig. 2A) and the brightfield channel (Fig. 2B)
revealed that intracellular aluminum was occasion-
ally found co-localized with AT8-reactive tau in the
cell soma of pyramidal neurons (Fig. 2D).
Similarly, lumogallion-reactive aluminum was
detected in neuronal cells in pia mater in the tem-
poral cortex of the same donor, as highlighted via
an intense orange fluorescence emission (Fig. 3A).
AT8 counter-immunolabelling of the identical tis-
sue section produced brown intraneuronal DAB
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Fig. 2. Intracellular aluminum in pyramidal neurons in the temporal cortex of a 57-year-old female Colombian donor with familial Alzheimer’s
disease. A) Intracellular aluminum (Al) in pyramidal neurons (orange). B) AT8 immunoreactive phosphorylated tau (pTau) in a single neuron
(black arrow) located via DAB staining (brown) and the absence of staining in an adjacent neuron (white arrow). C). Autofluorescence (green)
of the non-stained adjacent section highlighting deposits of intracellular lipofuscin (yellow). D) Merging of lumogallion and brightfield
channels depicting aluminum and pTau in an identical neuron (black arrow) and the absence of DAB staining in an adjacent neuron (white
arrow). Asterisks denote magnified inserts. Magnification: X 400, scale bars: 50 m.
precipitation of an NFT-like morphology (Fig. 3B).
The adjacent non-stained serial section yielded a
green autofluorescence emission with yellow punc-
tate lipofuscin deposits identified intracellularly
(Fig. 3C). Merging of the lumogallion and bright-
field channel demonstrated the co-localization of
aluminum and AT8-reactive tau in the same neuron
(Fig. 3D).
The co-localization of aluminum and immunore-
active tau was not restricted to the temporal lobe.
Such deposition was also noted in the parietal (see
Supplementary Figure 3) and frontal cortex (see
Supplementary Figure 4) of the same 57-year-old
female Colombian fAD donor. In both cases, alu-
minum was found intracellularly in neurons close
to the pia mater. The orange fluorescence intensity
produced was generally weaker in neurons in the
frontal lobe, though markedly brighter than green
autofluorescence typically noted for non-stained sec-
tions. AT8 immunolabelling produced dark brown
staining, resembling intracellular NFTs. In the iden-
tical neurons, aluminum was found co-localized with
AT8-labelled DAB-reactive tau deposits. In the
occipital lobe, few neurons produced a positive
lumogallion fluorescence signal for aluminum above
background autofluorescence.
Additional brain tissue sections of the temporal
lobe of fAD donors were investigated to support
observations of aluminum-rich NFTs. In the tem-
poral cortex of a 60-year-old male Colombian fAD
donor, intracellular lumogallion-reactive aluminum
produced an orange fluorescence emission that exhib-
ited a flame-like morphology (Fig. 4A). IHC for
phosphorylated tau revealed intracellular dark brown
DAB staining in the same neuron, appearing as a
characteristic flame-like NFT (Fig. 4B). Similar lipo-
fuscin loading was noted in the same cell via punctate
yellow autofluorescence of the non-stained adjacent
tissue section (Fig. 4C). Merging of lumogallion
fluorescence and the AT8 brightfield channel con-
firmed that both aluminum and immunolabelled tau
were intraneuronal and co-localized, of which both
adopted a flame-like structure, similar to that of NFTs
(Fig. 4D). Such confirmed similar observations made
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Fig. 3. Intraneuronal aluminum in the temporal cortex of a 57-year-old female Colombian donor with familial Alzheimer’s disease. A)
Intracellular aluminum (Al) in a neuron (orange). B) AT8 immunoreactive phosphorylated tau (pTau) located via DAB staining (brown).
C). Autofluorescence (green) of the non-stained adjacent section highlighting occasional deposits of intracellular lipofuscin (yellow). D)
Merging of lumogallion and brightfield channels depicting aluminum and pTau in the identical neuron. Asterisks denote magnified inserts.
Magnification: X 400, scale bars: 50 m.
of aluminum co-localized with DAB-reactive NFTs,
in different cortical regions of the same lobe (see
Supplementary Figure 5).
Phosphorylated tau immunostaining and
aluminum deposition in senile plaques
Senile plaques were frequently found to pro-
duce a bright orange fluorescence emission when
stained with lumogallion across all lobes investig-
ated (frontal, parietal, occipital, and temporal cortex)
from each Colombian fAD donor. For example, in
the temporal cortex of a 60-year-old male Colombian
fAD donor, a bright orange fluorescence emission
was noted in a senile plaque, in which yellow punc-
tate fluorescence of lipofuscin was found at its
periphery (Fig. 5A). Upon counter-staining against
phosphorylated tau using an AT8 primary antibody,
DAB-reactive staining was found in neuronal-like
bodies that, similarly to lipofuscin, were also located
at the periphery of the identical senile plaque
(Fig. 5B).
A weak green autofluorescence emission was
noted in the immediate vicinity of the same senile
plaque, with discreet particulate-like deposits of lipo-
fuscin located at its periphery (Fig. 5C). Merging
of the lumogallion fluorescence and the brightfield
channel highlighted the presence of aluminum in
the senile plaque core with no clear co-localization
to DAB-reactive neuronal bodies at its periphery
(Fig. 5D). Similar observations were made in larger
senile plaques (>50 m), in which a dark brown
AT8-reactive DAB staining was noted in peripheral
dystrophic-like neurites and discreet neuronal bodies,
depositing away from the aluminum-rich core regions
of senile plaques (see Supplementary Figure 6).
DISCUSSION
We have demonstrated the neuronal co-localiz-
ation of aluminum and phosphorylated tau in NFTs
in fAD donor brain tissue, carrying a PSEN1-
E280A mutation. Aluminum-specific fluorescence
microscopy utilizing the fluorophore lumogallion
revealed the presence of aluminum in neurons
290 M.J. Mold et al. / Aluminum and Tau in Familial AD
Fig. 4. Intraneuronal aluminum in the temporal cortex of a 60-year-old male Colombian donor with familial Alzheimer’s disease. A)
Intracellular aluminum (Al) in a neuron (orange). B) AT8 immunoreactive phosphorylated tau (pTau) located via DAB staining (brown)
appearing as flame-like NFT. C). Autofluorescence (green) of the non-stained adjacent section highlighting occasional deposits of intracellular
lipofuscin (yellow). D) Merging of lumogallion and brightfield channels depicting aluminum and pTau co-localized in the identical neuron.
Asterisks denote magnified inserts. Magnification: X 400, scale bars: 50 m.
co-deposited with neuropil-like threads [26]. The
latter was previously detected by the use of the
benzothiazole-based dye, thioflavin S (ThS), which
binds to -pleated sheet-like moieties, including
mature NFTs and A fibrils in senile plaques [29].
While a key benefit of ThS labelling is its abil-
ity to produce fluorescence only with mature and
pathologically-relevant misfolded amyloidogenic
proteins, such is not specific to hyperphosphorylated
tau in NFTs [29].
AT8 is an anti-tau primary antibody that recognizes
the well-characterized Ser202 and Thr205 epitopes
of phosphorylated tau [28]. Owing to the clear DAB
labelling above background at 1:1,000 dilutions of
the primary AT8 antibody, this concentration was
used for all subsequent IHC experiments identify-
ing NFTs. In cortical brain regions, AT8 revealed
intracellular pathological NFT inclusions. As the
most prominent of the AT-series monoclonal antibod-
ies directed against phosphatase-sensitive epitopes,
AT8 labels both intracellular and extracellular NFTs
as distinguished by the presence of collapsed den-
drites [30]. These late-stage or ghost-like tangles
that form extracellularly following apoptosis of the
affected neuronal cell show the distinctive absence
of a nucleus with no discernable cytoplasm [29–31].
Late-stage ghost NFTs frequently possess a central
void. Their characteristic presence adopts tangles of
a paired helical filament morphology, located in the
somatodendritic compartments of the ruptured cells
[3, 30, 31].
Herein, we identified AT8-immunoreactive ghost
NFTs co-localized with aluminum, confirming our
previous observations of ThS-reactive tangles in
identical neurons in the temporal cortex of a 45-year-
old female fAD donor [26]. As expected, the use of
IHC to detect phosphorylated tau was more sensi-
tive than fluorescent staining using ThS and showed
improvements in visualizing the various stages of tau
tangle formation [29, 32]. Aluminum was observed
co-located with NFTs across multiple brain regions,
including the frontal, temporal, and parietal cortex, of
which fewer positive staining examples were found
in the occipital cortex.
Of all lobes investigated, aluminum was found
most commonly co-located in NFTs in the temporal
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Fig. 5. Aluminum in a senile plaque in the temporal cortex of a 60-year-old male Colombian donor with familial Alzheimer’s disease. A)
Aluminum (Al) staining of a senile plaque (orange). B) AT8 immunoreactive phosphorylated tau (pTau) located via DAB staining (brown) in
dystrophic neurites (arrows) at the periphery of the identical senile plaque C). Autofluorescence (green) of the non-stained adjacent section
highlighting occasional deposits of intracellular lipofuscin (yellow). D) Merging of lumogallion and brightfield channels depicting aluminum
and pTau (arrows) in the identical senile plaque. Asterisks denote magnified inserts. Magnification: X 400, scale bars: 50 m.
cortex. The temporal cortex is of the first brain regions
in which tau is known to propagate as NFTs. The
expansion of NFT pathology in the brain is graded
via the Braak stages of severity, of which 0-IV ascribe
the confinement of NFT pathology to the medial
temporal lobe [33, 34]. At stage I, NFT pathol-
ogy is confined to the transentorhinal region, which
migrates to deeper entorhinal regions and into the
hippocampus at stage II. Widespread hippocampal
lesions are observed at stage III, spreading to the
medial temporal gyrus at stage IV [34]. Later stages
(V and VI) of disease progression are marked by NFT
deposition in the striate and parastriate regions of the
occipital cortex [34].
In living fAD donors carrying a PSEN1-E280A
mutation, positron emission tomography has revealed
that NFT formation ensues ten to fifteen years after
marked increases of soluble tau are typically detected
in the cerebrospinal fluid [35, 36]. Subsequent onset
to severe dementia arises approximately seven years
later, marking tau pathology as an essential biomarker
of early disease progression. As a consequence of
the late onset of tau pathology in the PSEN1-E280A
brain, such may account for the early and widespread
distribution of NFTs in the temporal cortex and per-
haps their association with aluminum [35, 36].
Elevated soluble cortical A in the same kindred
is mirrored by widespread senile plaque deposition,
preceding NFT formation in vivo [24, 35, 36]. There-
fore, the abundance of extracellular A depositing
as -pleated sheets in senile plaques would provide
numerous binding sites for aluminum before potential
competitive interactions with the intracellular phos-
phorylated binding sites available in NFTs [27]. Such
a mechanism may account for the high levels of alu-
minum observed in the brain tissue of fAD donors
carrying a PSEN1-E280A mutation versus donors
with neither a clinical nor pathological diagnosis of
neurodegenerative disease [23, 25, 37].
Interestingly, while numerous ghost NFTs were
present in the cerebral cortex of fAD donors that
produced positive DAB staining for phosphorylated
tau, their co-localization with aluminum was detected
less frequently. While immunoreactive phospho-
rylated tau was found co-located with aluminum
in cortical neurons, they were fewer in incidence
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than co-deposits of aluminum in the core of extra-
cellular senile plaques. Therefore, AT8 immuno-
labelling confirmed the preferential binding of
aluminum exhibited in senile plaques versus NFTs
[23, 26]. These data suggest that the co-deposition
of aluminum with A precedes that with NFTs.
Extracellularly deposited A may also be more
immediately available to bind aluminum versus intra-
cellular aggregates of tau. AT8 immunoreactive tau
was found deposited at the periphery of senile plaques
in both intracellular neuronal bodies and extracellu-
lar ghost NFTs. Lumogallion-reactive aluminum was
frequently observed in the cores of neuritic plaques
in which its deposition was less evident within sur-
rounding tau-reactive neurons.
In addition to AT8-labelled dystrophic neurites,
lipofuscin was also observed deposited at the periph-
ery of senile plaques. As a marker of lysosomal
degradation, autofluorescent lipid and misfolded
protein-rich deposits are known to accumulate in the
cytoplasm of neurons [38]. Aggregates of lipofus-
cin have previously been suggested to play an active
role in neurodegeneration [38, 39]. As a marker of
impeded lysosomal function and proteolytic activity,
the release of lipofuscin into the extracellular milieu
following neuronal death has been implicated in the
formation of senile plaques [39].
Failure in the misfolded protein response promotes
the formation of lipofuscin and its subsequent release
from dying cells, and hence, the presence of lipo-
fuscin in brain tissue sections increases upon ageing
[38]. Such may explain the intimate associations
observed between A and coronal lipofuscin in senile
plaques [37, 38, 40, 41]. In concert with A, co-
aggregated lipofuscin deposits bind aluminum that
may act further to exacerbate the accumulation of
aluminum in senile plaque cores, as has been pre-
viously reported in AD brain tissue [23, 37, 42].
Conversely, intracellular aluminum found in neu-
rons heavily laden with lipofuscin was not always
found co-located with NFTs. Therefore, intracellu-
lar lipofuscin presence may not necessarily dictate
aluminum binding as was observed herein in pyrami-
dal neurons in the temporal cortex of a 57-year-old
female Colombian fAD donor.
AT8-immunoreactive phosphorylated tau protein
and its silver-impregnated derivatives have previ-
ously been reported at the periphery of cored neuritic
plaques in the hippocampus of AD donors and within
dystrophic neurites surrounding senile plaques in
the neighboring entorhinal cortex [43–45]. Early
observations of Braak staging of NFT pathology
in AD highlighted the presence of AT8-reactive
NFTs in the amygdala of elderly (aged ≥ 70 years)
AD donors [33]. The appearance of tau deposit-
ing as NFTs has been predominantly reported in
pyramidal neurons upon labelling for phosphory-
lated tau. Therein, hyperphosphorylated tau filaments
were observed near A in approximately a third of
AT8-immunolabelled senile plaques [43]. Further-
more, the co-localization of tau in senile plaques
was not only restricted to AT8-reactive tau, as addi-
tional immunoreactivity to the phosphorylated-tau
Ser396 isoform was always detected [43]. Therefore,
our observations of coronal tau surrounding senile
plaques would be expected to originate from phos-
phorylated forms of the protein in either dystrophic
neurites or depositing as NFTs.
In summary, we have demonstrated the unequivo-
cal association of aluminum and phosphorylated tau
in NFTs in fAD. While aluminum binding to A
in senile plaques is expected in early disease pro-
gression concomitant with elevated amyloidogenic
protein levels, an association with tau may occur
at later disease stages [23, 24, 26, 35, 36]. Senile
plaques containing dystrophic neurites are associated
with neuronal death in AD, of which the ensuing
neurotoxicity may be synergistically mediated by
the co-existence of A and aluminum in these neu-
ropathological hallmarks [46–49]. Indeed, the latter
potentiates the redox cycling of iron in the presence
of A42, generating reactive oxygen species, includ-
ing the superoxide radical anion [50]. The subsequent
extracellular release of NFTs from dying neurons
may allow for a mechanism of aluminum binding
in senile plaques to phosphorylated tau, exposed in
filamentous regions of the misfolded protein [42].
Therapeutic approaches to reduce tau have been sug-
gested to ameliorate its synergistic interactions with
A, reducing tau pathology and subsequent neuronal
loss [51]. These data support the intricate associa-
tions of aluminum in the neuropathology of fAD, of
which its subsequent reduction may further therapeu-
tic benefits observed in ongoing clinical trials, in vivo
[52].
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